Literature DB >> 3282017

Enzyme-linked immunosorbent assay for human proapolipoprotein A-I using specific antibodies against synthetic peptide.

A Barkia1, C Martin, P Puchois, J C Gesquiere, C Cachera, A Tartar, J C Fruchart.   

Abstract

Apolipoprotein A-I (apoA-I), the major protein component of human high density lipoprotein, appears intracellularly as an intermediate precursor (proapoA-I) with a hexapeptide extension (Arg-His-Phe-Trp-Gln-Gln) at its amino terminus. To investigate the regulation of processes that regulate plasma apoA-I levels, a sensitive and simple assay for proapoA-I is required. We describe a specific enzyme-linked immunosorbent assay (ELISA) for quantification of proapoA-I using monospecific rabbit antibodies raised against the peptide: Arg-His-Phe-Trp-Gln-Gln-Asp-Glu-Pro. The monospecificity of antibodies to propeptide has been checked and no cross-reaction with mature apoA-I has been found although three first mature apoA-I amino acids (Asp-Glu-Pro) were included in the immunizing peptide. The assay is a non-competitive sandwich ELISA in which polystyrene microtiter plates were used with antibodies to propeptide adsorbed on the wells. After incubation with plasma samples, the bound proapoA-I was revealed by labeled rabbit polyclonal antibodies directed against mature apoA-I. The working range was 10 to 100 ng/ml, recovery of proapoA-I added to plasma was 94.6 to 106.5%, and the intra- and interassay coefficients of variation were 3.8% and 7.9%, respectively. A delipidation step using diisopropylether-n-butanol was necessary to expose antigen sites of proapoA-I in native lipoproteins. Mean level of proapoA-I in normal subjects was 87 +/- 15 micrograms/ml. It represented 7.1% of total apoA-I while in Tangier serum it represented 29%.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3282017

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  4 in total

1.  Cubbing in proapolipoprotein maturation.

Authors:  Godfrey S Getz; Catherine A Reardon
Journal:  J Lipid Res       Date:  2011-09-06       Impact factor: 5.922

2.  Regulation of apoAI processing by procollagen C-proteinase enhancer-2 and bone morphogenetic protein-1.

Authors:  Jian Zhu; Joseph Gardner; Clive R Pullinger; John P Kane; John F Thompson; Omar L Francone
Journal:  J Lipid Res       Date:  2009-02-23       Impact factor: 5.922

3.  Exocytosis of Neutrophil Formyl peptide receptor-like 1 (fPRL1) results in downregulation of cytoplasmic fPRL1 in patients with purulent dermatitis.

Authors:  Eiji Ohara; Yoshitaka Kumon; Toshihiro Kobayashi; Hiroaki Takeuchi; Tetsuro Sugiura
Journal:  Clin Vaccine Immunol       Date:  2007-04-25

4.  Identification of high-affinity VEGFR3-binding peptides through a phage-displayed random peptide library.

Authors:  Li Feng Shi; Yan Wu; Cai Yun Li
Journal:  J Gynecol Oncol       Date:  2015-07-17       Impact factor: 4.401

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.